Metastat Inc · OTC:MTST
Metastat — Investor Presentation (September 2015)
26 slides from Metastat's investor presentation, Sep 9, 2015
Slide 1: MetaStat, Inc. Corporate Presentation Fall 2015
MetaStat, Inc. Corporate Presentation Fall 2015 @MetaStat Be
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by the safe har
Slide 3: Investment Highlights
Investment Highlights Experienced Management Team, Board of Directors, and Scientific/Clinical Advisors * Management team with experience from Amgen, Exosome Dx, GE Healthcare, HistoRx, Incyte, Javalin, Millennium, PolaRx, Pfizer, Roche Diagnostics, Roche Molecular Systems; * Advisors from Massachus
Slide 4: MetaStat, Inc. Company Profile
MetaStat, Inc. Company Profile Who we are: + Publicly-traded (OTCOB:MTST) pre-commercial molecular diagnostic and digital pathology company; + Experienced Senior Management team and Board of Directors; + SAB made up of leading experts and oncologists from Albert Einstein College of Medicine, Harvard
Slide 5: Diagnostic Product Portfolio
Diagnostic Product Portfolio MetaStat is developing a platform with multiple diagnostic applications cANCER Diagnostics Breast A diagnostic that predicts the probability of MetaSite Breast™ metastasis based on the density of Immunohistochemistry test Diagnostic Breast ‘A diagnostic platform that pre
Slide 6: 2015/2016 Company News Flow
2015/2016 Company News Flow Assay Method Development and Analytical Validation + MetaSite™ Breast assay development and analytical validation - Q3'15, + MenaCale™ assay development and analytical validation ~ Q4’15 Clinical Development Program + Prognostic Kaiser cohort MetaSite™ replication study (
Slide 7: Clinical Validation and Utility Study Plan
Clinical Validation and Utility Study Plan 2 key pillars of clinical evidence - chemo-predictive and prognostic data to support oncologist decisions and payor reimbursement Prognostic Kaiter Permanente Cohort MetaSite Replication Study (Kaizer Cohort A) -topline data Q4'15, ‘+ -Replicatethe Rohan et
Slide 8: Experienced Senior Management Team
Experienced Senior Management Team with Deep Understanding of the Clinical, Scientific, and Business Aspects of Oncology Healthcare Management Team [ome [Tle emerienee ‘Doulas Hamilton BSc, MBA ‘Michael Donoven ‘MD, PhD ‘Mark Gustavson Pho. Daniel Schneiderman Heiner Dreismann, PhO. President and Ch
Slide 9: Board of Directors with Significant Leadership, Business, M&A, Capital Markets Experience
Board of Directors with Significant Leadership, Business, M&A, Capital Markets and Commercial Experience Board of Directors a Richard J. Berman, 8.S., Mpa Driscoll, Bsc. Oscar Bronsther, M.D. Philip Goodeve, B.Com., MBA Johan M. (Thijs) ‘Spoor Chairman of the Board irector Director Director Director
Slide 10: Leading Scientific and Clinical KOL Advisory Board Members
Leading Scientific and Clinical KOL Advisory Board Members [nae tsnsaticion | (Oscar Bronsther, M.D. = ClinkslProtess of urge George Washington University * Former Chairmen Secton of GeneralSurgery now FairaxHosptal + _ Former Chairmancf the Boar ofk ler Permanente National TransplarNework ‘Alber Ei
Slide 11: Company Developments & Key Highlights
Company Developments & Key Highlights 1) Core technology patents issued (late 2013 and 2014) 2) Closed $5.7 million financing and note conversion (July 2014) + Eliminated debt and cleaned-up the balance sheet 3) Peer-reviewed results from pivotal clinical study of 481 patients with early stage breas
Slide 12: Market Opportunity: Breast Cancer Diagnostics
Market Opportunity: Breast Cancer Diagnostics Established market with clinical practice guidelines from American Society Clinical Oncologists ASCO & NCCN recommending breast cancer diagnostic testing for all patients* Commercially available gene panel testshave limited utility; * 40% of the invasive
Slide 13: Large Potential Addressable U.S. Market for MetaStat
Large Potential Addressable U.S. Market for MetaStat Number of new Addressable Potential cases Market Size Product ‘cases per year per year ($ mm) Mena - Breast 232,670 80 186,136 $271 MenaCalc - Lung 224,201 Sit 114,347 $107 MenaCalc - Prostate 233,300 90 209,970 $196 MenaCale - CRC 136,830 36 49,2
Slide 14: Challenges Facing Practicing Oncologists
Challenges Facing Practicing Oncologists Aggressive disease leading to systemic metastasis is responsible for 90% of solid tumor cancer related deaths. However, only 30-35% of early stage newly diagnosed invasive breast cancer is aggressive and has the potential to spread. The challenge for practici
Slide 15: MetaStat's Diagnostics Provide Answers to the Challenges Facing Practicing Oncologists
MetaStat’s Diagnostics Provide Answers to the Challenges Facing Practicing Oncologists Our tests provide oncologists access to actionable information to influence treatment decisions by addressing different questions depending on the molecular subtype, clinical setting, geographic practice patterns,
Slide 16: The MetaStat Solution: Superior Diagnostics with Actionable Information
The MetaStat Solution: Superior Diagnostics with Actionable Information ‘* Personalize optimal treatment strategies for the individual cancer patient; * Identify patients at high risk with aggressive tumors that are more likely to spread and who would maximally benefit from neo-adjuvant chemotherapy
Slide 17: MetaSite and MenaCalc Fit into Existing Clinical Workflow
MetaSite and MenaCalc will Easily Fit into the Existing Clinical Workflow with a 3-5 Day Turn-around Time Current Workflow Patient Pysion Patholoey tab | ,Zesonine Provides Teeatment ‘Teeatment Options & Disgnostic Report Metastatic Workup Molignant or Benign 7 CUA Lab re & Rick Profle analysis 2 @M
Slide 18: Diagnostic Tests Across the Patient Journey
Diagnostic Tests Across the “Patient Journey” ERIPR hormone status HER2 analysis FTestior BRCAT, BROAD, PALB2 gene mutations Epigeneticmetasticisk determination Erereee Metasite Breast, MenaCale (MetaStat) (Uiyriad Genetics) Gene panel-vasedriskofrecurence ‘Oncotype Dx (Genomic Health) MammaPrint®(A
Slide 19: Competitive Landscape
Competitive Landscape Product ‘Oncotype DX? ‘MammaPrint® Prosigna® mica Menacale™ Company Genomic ‘eelth Agenda Nonostring Novartis (Genoptix) Metastat Metastat 2h gene panel 70 gene pane! 50 gene panel ER, PR, HER2, K-67 Metasite density RT-PCR (maNA expression) Microarray (mRNA expression) Platfor
Slide 20: MetaSite/MenaCalc Assays have Existing CPT Codes
MetaSite™/MenCalc™ Assays have Existing CPT Codes Reimbursement MetaStat CPT Code 88361 MetaSite Breast™ and MenaCalc™ diagnostic tests are eligible for 3rd party reimbursement under already established medical billing codes * CPT Code 88361: Morphometric analysis, tumor immunohistochemistry, quanti
Slide 21: Regulatory Pathway
Regulatory Pathway Two Pathways to Market * Lab Derived Test (LOT) regulated under CLIA (Clinical Laboratory Improvement Amendments); * Invitro Diagnostic (IVD) regulated by FDA, $10(k) submission and approval. Preferred Approach to Offer LDT from Central Laboratory * Faster to market, less costly,
Slide 22: MetaStat has Strong IP Position
MetaStat has Strong IP Position Broad Intellectual Property Position; + 12 patents filed; * 3 UScore patents issued LOE - 2030 Y 8,642,277 — 02/04/2014 ¥ 8,603,738 ~ 12/10/2013 Y 8,298,756 - 10/30/2013 Amster, Rothstein, and Ebenstein, LLP & Morgan, Lewis, and Bockius, LLP Oversee our Patent Portfol
Slide 23: Back-up Slides
Back-up Slides
Slide 24: The MetaSite: Capturing the Tumor MicroEnvironment
The MetaSite: Capturing the Tumor MicroEnvironment ye The Window or Portal Where Systemic Metastasis Takes Place: Three cells in apposition * Red Metastatic Cell (Mena +) — Pan-Mena MAB * Blue Endothelial Cell— CD31 MAB + Brown Macrophage - CD68 MAB Triple Immunohistochemical Stain @MetaStat
Slide 25: Initial Market Opportunity - $271 million
Initial Market Opportunity - $271 million Total Breast Cancer Market 20146 ‘Addressable Patient Population 252,670 patient: — 386,136 patients — $228 millon $271 millon ‘one sharepoint ofthe addressable marketis worth $27 milion based ‘on estimated average elmbursementrat per test Iacketpenetraton c
Slide 26: Compelling Story: Positive Press Coverage
Compelling Story: Positive Press Coverage Game Removing ener Meta ht techno ib ate pret freee wl th e ‘SWO rd See of Damocles’ sh ‘/Medical Device Daily are peer ‘most breast cancer patients NewCo on the Go: MetaStat’s summer: new financing, spin-off, and positive study results 7 medGadget Predictin